The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Share News (ORPH)

  • There is currently no data for ORPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Open Orphan CEO Steps Down; Inks New Challenge Study Contract

Mon, 04th May 2020 14:35

(Alliance News) - Open Orphan PLC on Monday announced that Chief Executive Trevor Phillips will be standing down and said it has signed a new contract with a US biotechnology.

Shares in the pharmaceutical services firm were up 10% at 9.90 pence in London in afternoon trading.

Philips will stay in his role until June end but has departed the board with immediate effects. He joined hVIVO at the end of 2018 and led hVIVO's merger with Open Orphan. Executive Chair Cathal Friel will lead Open Orphan.

The new contract is for Open Orphan to provide a human challenge study in respiratory syncytial virus, a highly contagious viral disease and among the most common causes of pneumonia and bronchiolitis. Challenge studies purposefully expose healthy volunteers to an infectious disease.

The biotechnology company's name was not disclosed, though Open Orphan expects to receive around GBP3.5 million of revenue in 2020 from the study.

Open Orphan acquired Venn Life Sciences Holdings PLC in January, the same month its completed its merger with hVIVO PLC. The study will use the clinical research organisation services of hVIVO and Venn and will take place at hVIVO's London-based quarantine unit in the third quarter of 2020.

Friel said: "Firstly, I would like to thank Trevor for his help merging Open Orphan and hVIVO. Trevor had previously successfully right sized and focused hVIVO and our refreshed management team is now focused on delivering growth at a very exciting time for the company.

"The signing of this new GBP3.5 million contract with a US biotechnology company is further evidence of this exciting time as we successfully convert Open Orphan's pipeline of prospects into formal customer contracts. Open Orphan will be utilising its complementary in-house [clinical research organisation] services of hVIVO and Venn to deliver this contract. This contract demonstrates the Open Orphan and hVivo group's focus on building long term contracts with recurring revenues to deliver future profitability while ensuring rationalising the business and reduce costs."

By Anna Farley; annafarley@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
9 Jul 2021 11:42

Open Orphan inks contract with AIM ImmunoTech to test Ampligen drug

Open Orphan inks contract with AIM ImmunoTech to test Ampligen drug

Read more
9 Jul 2021 10:52

AIM WINNERS & LOSERS: Evgen disappointed as SFX-01 flops study hurdle

AIM WINNERS & LOSERS: Evgen disappointed as SFX-01 flops study hurdle

Read more
9 Jul 2021 10:20

Open Orphan subsidiary scores 'significant contract' with AIM ImmunoTech

(Sharecast News) - Clinical research organisation Open Orphan's hVIVO subsidiary has signed "a significant contract" to test AIM ImmunoTech's antiviral candidate, Ampligen.

Read more
17 Jun 2021 14:34

Cathal Friel-led Poolbeg Pharma set to float on AIM

(Sharecast News) - Infectious disease specialist Poolbeg Pharma is to list on the London Stock Exchange's junior market, AIM, with a view to raising the funds needed to develop its product pipeline.

Read more
17 Jun 2021 14:05

Open Orphan reports widened 2020 loss; Poolbeg mulls London float

Open Orphan reports widened 2020 loss; Poolbeg mulls London float

Read more
17 Jun 2021 11:43

AIM WINNERS & LOSERS: Midatech Pharma up 90% on Q-Sphera breakthrough

AIM WINNERS & LOSERS: Midatech Pharma up 90% on Q-Sphera breakthrough

Read more
16 Jun 2021 16:00

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
19 May 2021 19:33

TRADING UPDATES: Young's mulls asset sale; Ceres gets China investment

TRADING UPDATES: Young's mulls asset sale; Ceres gets China investment

Read more
10 May 2021 13:37

TRADING UPDATES: Begbies buys finance broker; Amino Tech makes US bid

TRADING UPDATES: Begbies buys finance broker; Amino Tech makes US bid

Read more
10 May 2021 09:30

Open Orphan subsidiary signs contract to make Covid-19 challenge virus

(Sharecast News) - Specialist pharmaceutical services contract research organisation Open Orphan announced on Monday that its subsidiary hVIVO has signed a contract with Imperial College London, as part of a Wellcome Trust-funded initiative to manufacture a SARS-CoV-2 challenge virus.

Read more
6 May 2021 15:33

EXECUTIVE CHANGES: New Cenkos CEO gets FCA nod; Feedback hires CFO

EXECUTIVE CHANGES: New Cenkos CEO gets FCA nod; Feedback hires CFO

Read more
9 Apr 2021 10:33

Open Orphan launches new data platform to combat infectious diseases

Open Orphan launches new data platform to combat infectious diseases

Read more
26 Mar 2021 14:36

TRADING UPDATES: Renew to buy J Browne; Idox in good start to year

TRADING UPDATES: Renew to buy J Browne; Idox in good start to year

Read more
25 Mar 2021 17:14

TRADING UPDATES: SpaceandPeople swings to loss in 2020 amid virus

TRADING UPDATES: SpaceandPeople swings to loss in 2020 amid virus

Read more
25 Mar 2021 15:34

Open Orphan makes progress with Covid-19 characterisation study

(Sharecast News) - Specialist pharmaceutical services clinical research company Open Orphan updated the market on its world-first Covid-19 characterisation study on Thursday, reporting that the first three volunteers had now completed the quarantine phase.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.